Johnson & Johnson gains approval for Imaavy to treat a rare blood disorder.
The U.S. Food and Drug Administration has granted approval for Johnson & Johnson’s Imaavy to treat a rare blood disorder. The decision follows standard regulatory review processes.
Further details on the drug’s availability or clinical specifics were not immediately available.
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
